Survival in patients with HR+/HER2- metastatic breast cancer treated with initial endocrine therapy versus initial chemotherapy. A French population-based study.

Fiche publication


Date publication

juillet 2020

Journal

British journal of cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Pr COUTANT Charles, Dr DABAKUYO-YONLI Sandrine, Dr LADOIRE Sylvain, Pr QUANTIN Catherine, Dr BILLA Oumar


Tous les auteurs :
Simon J, Chaix M, Billa O, Kamga AM, Roignot P, Ladoire S, Coutant C, Arveux P, Quantin C, Dabakuyo-Yonli TS

Résumé

According to international guidelines, endocrine therapy (ET) is the preferred option for hormone receptor-positive (HR+) HER2-negative (HER2-) metastatic breast cancer. In spite of clear recommendations, these are not strictly followed in daily practice. The objectives of this study were to investigate the effect of the first anti-metastatic treatment therapy choice on progression-free survival (PFS) and overall survival (OS).

Référence

Br. J. Cancer. 2020 Jul 17;: